
Higher concealment behavior for patients with multiple sclerosis was associated with higher anxiety, but not depression.
Higher concealment behavior for patients with multiple sclerosis was associated with higher anxiety, but not depression.
The global head of medical affairs-neurology at Janssen Pharmaceutical provided background on the need for real-world studies and how they can accurately portray a disease community.
The authors concluded that longitudinal optical coherence tomography measures may be sensitive to changes in cognitive function and may be useful for monitoring neuroprotective therapies.
Neurology News Network for the week ending February 27, 2021.
Researchers from the University of Washington Medical Center analyzed data from almost 10,000 infusions of natalizumab.
Data from a pair of posters suggest that cognition, fatigue, and depression all impact social activity limitations in people with MS, rather than walking impairment alone.
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 26, 2021.
Researchers investigated the test, which is normally used to differentiate people with MS from healthy controls, in a population of those with multiple sclerosis.
The fellow of autoimmune neurology at Massachusetts General Hospital discussed the analysis his team conducted to clarify the known associations.
The trial of anakinra is underway, while the trial for tolebrutinib is undergoing regulatory review.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Martin, PhD.
The authors concluded that this approach may be applied in fatigue management treatment protocols, without increasing symptoms, in patients with multiple sclerosis.
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.
The antisense oligonucleotide casimersen will be branded as Amondys 45 and is currently being assessed in the ESSENCE phase 3 clinical trial (NCT02500381).
The effect of cladribine on CD8+ T lymphocytes varied by age, with steady increases shown in the younger population whereas there were fluctuations observed in the older group.
The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.
Researchers retrospectively analyzed patient follow-ups and found that 50% of patients were ultimately diagnosed with multiple sclerosis.
Advancements in gene therapy approaches have opened the door for a glimpse into the future of care for a number of diseases.
Tavapadon’s rare combination of efficacy and minimal adverse effects may indicate a step forward in the treatment of Parkinson disease.
Ahead of sessions kicking off on February 25, the ACTRIMS committee offered a look into what data, plenary talks, and developments are set to be presented at the upcoming ACTRIMS Forum 2021.
Similar proportions of both in-clinic and telemedicine patients had modified Rankin scale score improvements.
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical provided his expectations for the upcoming ACTRIMS Forum.
The director and founder of the Sleep Centers of Middle Tennessee compared the integrated care model of ISPs to the transactional model of DMEs.
The duo from Cleveland Clinic discussed their recently initiated study which will evaluate the neuroprotective features of home-based intervention in high-risk individuals for Alzheimer disease.
The director of Neurology and the Memory and Aging Program at Butler Hospital and principal investigator in the aducanumab clinical trial program discussed the investigational agent and the current landscape of care.
The assistant professor of pediatric neurology at the Washington University in St. Louis spoke to the insights of a recent survey she and colleagues conducted.
A recent study investigated self-reported outcomes of preventive treatment prior to the introduction of calcitonin gene related peptide (CGRP) receptor targeting.
Factors such as previous emergency department visits, hypertension, and tobacco use disorder were related to future migraine-related emergency department visits.
The assistant professor of neurology at Thomas Jefferson University gave background on what other studies have observed brain implants for poststroke patients and how they differ from his work.
A pair of migraine experts explores several topics in the acute treatment of migraine, including recent therapeutic innovations.